DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 27, 2006; DOI: 10.1124/dmd.105.007567


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.007567v1
34/4/636    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garland, M.
Right arrow Articles by Stark, R. I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garland, M.
Right arrow Articles by Stark, R. I


Received for publication October 5, 2005.
Revised January 24, 2006.
Accepted for publication January 25, 2006.

Fetal morphine metabolism and clearance are constant during late gestation

Marianne Garland 1*, Kirsten M Abildskov 1, Samantha Taylor 1, Kenza Benzeroual 1, Casper S Caspersen 1, Sylvia E Arroyo 1, Tung-Wah Kiu 1, Boris Reznik 1, Piper Weldy 1, Salha S Daniel 1, Raymond I Stark 1

1 Columbia University

* Address correspondence to: E-mail: mg71{at}columbia.edu

Abstract

Fetal metabolism significantly contributes to the clearance of drugs from the fetus. To understand how the changes in fetal metabolism expected in late gestation alter fetal drug clearance, serial measurements of morphine metabolism were made in the fetal baboon over the latter third of gestation. Clearance and metabolism were evaluated in the context of fetal growth, onset of labor, and the administration of classical enzyme induction agents. Morphine, a probe substrate for the enzyme uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7), was continuously infused to chronically catheterized fetal baboons while measuring morphine, morphine-3-{beta}-glucuronide (M3G), and morphine-6-{beta}-glucuronide (M6G) concentrations. In some animals, intermittent infusions of the metabolites provided estimates of metabolite clearance, and hence, the rate of formation of metabolites and metabolic clearance. Overall, metabolic clearance of morphine from the fetus was 27 ± 9.0 ml.min-1 or 32% of total clearance. This is similar to the overall clearance in the adult baboon when standardized to weight. No change in any measure of metabolism or clearance of morphine or its glucuronide metabolites was found with gestational age, the presence of labor, or administration of UGT enzyme induction agents. Interpreting these findings using a physiologically based approach suggests that the intrinsic clearance of the fetal liver toward morphine is of sufficient magnitude that fetal hepatic clearance is flow limited. The implication of a high intrinsic clearance is for significant placento-hepatic first pass metabolism when drugs are administered to the mother. The previously held view of the "inadequacy of perinatal glucuronidation" needs to be reconsidered.


Key words: developmental pharmacology, drug clearance, drug disposition, fetal drug metabolism, HPLC, induction, metabolite kinetics, pharmacokinetics, phase II drug metabolism, UDP glucuronyltransferases


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Garland, K. M. Abildskov, T.-w. Kiu, S. S. Daniel, P. Weldy, and R. I. Stark
Placental Transfer and Fetal Elimination of Morphine-3-{beta}-glucuronide in the Pregnant Baboon
Drug Metab. Dispos., September 1, 2008; 36(9): 1859 - 1868.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.